Page last updated: 2024-12-07
adp-ribosylarginine
Description
ADP-ribosylarginine: RN given refers to (L-Arg-D-ribofuranosyl)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (21)
Synonym |
C01201 , |
n(omega)-(adp-d-ribosyl)-l-arginine |
nomega-(adp-d-ribosyl)-l-arginine |
adp-ribosylarginine |
f2r , |
adenosine 5'-{3-[1-(n(omega)-arginino)-1-deoxy-alpha-d-ribofuranos-5-yl] dihydrogen diphosphate} |
CHEBI:15827 |
alpha-adp-ribosylarginine |
unii-d5024cp23u |
l-ornithine, n5-(((5-o-(hydroxy(phosphonooxy)phosphinyl)-alpha-d-ribofuranosyl)amino)iminomethyl)-, p'->5'-ester with adenosine |
l-ornithine, n5-(imino(alpha-d-ribofuranosylamino)methyl)-, (5'->p')-ester with adenosine 5'-(trihydrogen diphosphate) |
D5024CP23U , |
l-ornithine, n5-(imino(.alpha.-d-ribofuranosylamino)methyl)-, (5'->p')-ester with adenosine 5'-(trihydrogen diphosphate) |
103960-56-1 |
.alpha.-adp-ribosylarginine |
l-ornithine, n5-(((5-o-(hydroxy(phosphonooxy)phosphinyl)-.alpha.-d-ribofuranosyl)amino)iminomethyl)-, p'->5'-ester with adenosine |
adp-ribosyl-l-arginine |
Q27098247 |
l-ornithine, n5-[imino(alpha-d-ribofuranosylamino)methyl]-, (5'-->p')-ester with adenosine 5'-(trihydrogen diphosphate) |
DTXSID801107506 |
AKOS040750151 |
Roles (1)
Role | Description |
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
L-arginine derivative | A proteinogenic amino acid derivative resulting from reaction of L-arginine at the amino group, the carboxy group, or the guanidyl group, or from the replacement of any hydrogen of L-arginine by a heteroatom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 5 (31.25) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |